Josylin Ekochu Arimpa Bananuka
ID:
|
Corporate Governance Practices and Performance of Pharmaceutical Manufacturing Firms in Uganda
REFNo: SS571ES
i. To analyze the effect of corporate leadership on the performance of pharmaceutical manufacturing firms in Uganda
ii. To assess the effect of boards of directors on the performance of pharmaceutical manufacturing firms in Uganda
iii. To investigate the consequences internal control systems have on the performance of pharmaceutical manufacturing firms in Uganda
|
Uganda |
2021-07-09 |
2024-07-09 |
Social Science and Humanities |
|
Degree Award |
|
Francis Ocheng
ID:
|
Helichrysum odoratissimum: Isolation and identification of bioactive compounds and their effects on oral bacteria
REFNo: HS1441ES
2-To determine whether the isolated and purified compounds from Helichrysum odoratissimum maintain their antibacterial effects on oral bacteria,1-To isolate and identify the bioactive compounds in the plant Helichrysum odoratissimum plant extracts ,The general objective of the study is to isolate and identify the bioactive compounds in the Helichrysum odoratissimum plant extracts and also further investigate the effects of the isolated compounds on oral bacteria ,
|
Uganda |
2021-07-09 |
2024-07-09 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Catriona Waitt John
ID: UNCST-2019-R001068
|
Implementation of a "bundle of care" to improve anticoagulation control in patients receiving warfarin in Uganda and South Africa
REFNo: HS1422ES
Primary objective is to evaluate whether implementation of warfarin bundle improves time in therapeutic range
Secondary objectives are:
-To evaluate whether implementation of the warfarin bundle improves time to achieving a therapeutic INR
-Whether implementation of the warfarin bundle affects the occurrence of adverse events(death, bleeding and thrombotic events)
-whether staff find the interventions contained in the bundle acceptable
-To explore patients' experiences and acceptability of the package of care, and
-Whether the bundle represents good value for money
|
UK |
2021-07-09 |
2024-07-09 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Maureen Ayikoru
ID:
|
REVISED PROPOSAL IN RESPONSE TO THE OUTCOME OF ROUND 1 OF COMMITTEE REVIEW OF THE PROJECT “INDIRECT IMPACTS OF COVID-19 ON HEALTHCARE SYSTEMS: A CASE STUDY OF UGANDA’S HEALTHCARE PROFESSIONALS”
REFNo: HS1524ES
To document what lessons can be learnt from Uganda’s response to COVID-19,To analyse the impact of information and communication technologies and the media, including digital, print and broadcast media in containing the COVID-19 pandemic in Uganda.,To analyse what if any, political economy factors influence misinformation, resource reallocation and prioritisation during the ongoing pandemic and to document the perceived effects on the entire healthcare system including those most vulnerable,To identify what threats COVID-19 has had on physical, psychosocial, and overall well being of HCPs and to assess what if any formal and informal coping mechanisms have so far been available to them,To generate empirical evidence on the indirect impacts of Uganda’s response to COVID-19, focusing on the healthcare professionals.,
|
Uganda |
2021-07-09 |
2024-07-09 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Kamya Moses
ID: UNCST-2020-R014203
|
Efficacy and safety of artemether-lumefantrine, pyronaridine-artesunate, artesunate-amodiaquine and dihydroartemisinin – piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda.
REFNo: HS1363ES
The general objective of this study is to assess the therapeutic efficacy and safety of artemether-lumefantrine (AL), pyronaridine-artesunate (PA), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated P. falciparum malaria in three sentinel sites in Uganda.
The primary objectives are:
• to measure the clinical and parasitological efficacy of 4 artemisinin-based combination therapies (ACT), artemether-lumefantrine (AL) Pyronaridine-artesunate (PA), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP).
• to differentiate recrudescence from new infection of Plasmodium falciparum by molecular techniques.
The secondary objectives are:
• to evaluate the incidence of adverse events; and
• to determine the polymorphism of molecular markers mediating resistance for Artemsinin, Pyronaridine, Piperaquine and Lumefantrine resistance.
• to determine the blood concentration of Lumefantrine after treatment with Artemether- Lumefantrine .
|
Uganda |
2021-07-08 |
2024-07-08 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|